Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 1277-1303. PMID: 34781268, DOI: 10.6004/jnccn.2021.0053.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHistiocytic neoplasmsNCCN Clinical Practice GuidelinesCommon histiocytic disorderRare hematologic disorderRosai-Dorfman diseaseTreatment of adultsClinical practice guidelinesErdheim-Chester diseaseLangerhans cell histiocytosisNCCN guidelinesSelect patientsSystemic therapyLymph nodesClinical presentationMild diseaseCell histiocytosisHematologic disordersHistiocytic disorderPractice guidelinesOptimal managementPatientsNeoplasmsSoft tissueDiseaseDisordersIncidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open 2020, 3: e1918668. PMID: 31913492, PMCID: PMC6991246, DOI: 10.1001/jamanetworkopen.2019.18668.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantMucosal barrier injury laboratoryMBI-LCBIOutcomes of patientsStem cell transplantBloodstream infectionsCumulative incidenceCell transplantRisk factorsDay 100First allogeneic hematopoietic stem cell transplantMarrow Transplant Research databaseHost disease (GVHD) prophylaxisLansky performance statusTransplant-related mortalityOne-year mortalityTranslocation of bacteriaCord blood graftsCause of deathChronic graftConsecutive pediatricHost diseaseMyeloablative conditioningAdult patients